Evidence map›Paper›PMID 36653854›Full record

ArticleInternational journal of retina and vitreous2023

A customized regimen of intravitreal aflibercept for the treatment of choroidal neovascularization secondary to different chorioretinal diseases.

Magdy Moussa, Mahmoud Leila, Mayada Ali Mohamed, Ahmed Osama Hashem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of retina and vitreous, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Magdy MoussaOphthalmology department, Faculty of Medicine, Tanta University, El Bahr Street, Tanta Qism 2, Gharbia Governorate, Tanta, 31111, Egypt. magdymoussa60@gmail.com.
Mahmoud LeilaRetina department, Research Institute of Ophthalmology (RIO), Giza, Egypt.
Mayada Ali MohamedOphthalmology department, Faculty of Medicine, Kafr El Sheikh University, Kafr El Sheikh, Egypt.
Ahmed Osama HashemOphthalmology department, Faculty of Medicine, Kafr El Sheikh University, Kafr El Sheikh, Egypt.
Kafrelsheikh University · EGResearch Institute of Ophthalmology · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the response of CNV secondary to chorioretinal diseases to IVA and to explore the adequate dosing regimen and the long-term results.

methodsA retrospective study including patients with treatment-naïve active CNV secondary to chorioretinal diseases. All patients received an initial IVA injection followed by a PRN regimen. The main outcome measures were improvement of BCVA, improvement of anatomical morphology and vascularity of the CNV on SS-OCT, and SS-OCTA, respectively, and ocular or systemic complications attributed to IVA.

resultsThe study included 17 eyes of 15 patients. Nine patients (60%) were females. The median age was 20 years. The main primary chorioretinal disease was vitelliform macular dystrophy (29%). The mean baseline BCVA was 0.16. The mean follow-up period was 15 months. Final BCVA improved by a mean of 6 lines. The CNV regressed or became inactive in all eyes. The median number of IVA injections was 2. There were no ocular or systemic complications attributed to IVA.

conclusionThe customized IVA regimen is effective in inducing long-term regression of secondary CNV and in improving BCVA. Multimodal imaging is fundamental in establishing the diagnosis of CNV, and in monitoring its response to IVA.

Indexed as

CNV secondary to chorioretinal diseasesCustomized IVA regimenIntravitreal afliberceptSecondary CNV

Identifiers

PMID36653854
PMCPMC9847200
OpenAlexW4317105229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.